These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 2783379

  • 1. Marked reduction of subcutaneous tumor growth by intraperitoneal administration of recombinant human interleukin 2 with a cell accumulator, proteose-peptone, in mice.
    Tanida S, Uchida H, Taniguchi K, Nomoto K.
    Cancer Res; 1989 Jan 15; 49(2):284-8. PubMed ID: 2783379
    [Abstract] [Full Text] [Related]

  • 2. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 3. Combination treatment with irritant and recombinant interleukin 2 in the peritoneal cavity for evoking effective anti-tumor activity: generation of lymphokine-activated killer cells and tumor-specific killer cells.
    Uchida H, Taniguchi K, Nomoto K.
    Jpn J Cancer Res; 1990 Apr 01; 81(4):416-24. PubMed ID: 2114394
    [Abstract] [Full Text] [Related]

  • 4. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R, Kitagawa T, Koizumi K, Sato K, Homma M.
    J Biol Response Mod; 1989 Dec 01; 8(6):676-90. PubMed ID: 2600605
    [Abstract] [Full Text] [Related]

  • 5. Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.
    Naruo KI, Hinuma S, Shiho O, Houkan T, Ootsu K, Tsukamoto K.
    Clin Exp Immunol; 1989 May 01; 76(2):278-83. PubMed ID: 2788049
    [Abstract] [Full Text] [Related]

  • 6. [Combined effect of intraperitoneally administered OK-432 and recombinant interleukin (rIL-2) against mouse tumors].
    Fujioka T, Shiraishi M, Tanji S, Koike H, Kumagai K, Kubo T, Ohhori T.
    Nihon Gan Chiryo Gakkai Shi; 1989 May 20; 24(5):948-56. PubMed ID: 2789265
    [Abstract] [Full Text] [Related]

  • 7. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 8. Cytotoxic T-cell-mediated antitumor effect of levamisole against murine syngeneic fibrosarcoma.
    Gomi K, Morimoto M, Nomoto K.
    Cancer Res; 1982 Oct 15; 42(10):4197-202. PubMed ID: 6980702
    [Abstract] [Full Text] [Related]

  • 9. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct 15; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 10. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ, Krosnick JA, Rosenberg SA.
    J Immunol; 1989 Jan 15; 142(2):726-33. PubMed ID: 2783444
    [Abstract] [Full Text] [Related]

  • 11. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
    Harada M, Matsuzaki G, Yoshikai Y, Kobayashi N, Kurosawa S, Takimoto H, Nomoto K.
    Cancer Res; 1993 Jan 01; 53(1):106-11. PubMed ID: 8093229
    [Abstract] [Full Text] [Related]

  • 12. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
    Hinuma S, Naruo K, Shiho O, Tsukamoto K.
    Immunology; 1986 Oct 01; 59(2):251-9. PubMed ID: 3490435
    [Abstract] [Full Text] [Related]

  • 13. [Activation and regulation of macrophages induced by inoculation of cryodestroyed tumor cells].
    Tsujino M.
    Osaka Daigaku Shigaku Zasshi; 1990 Jun 01; 35(1):180-205. PubMed ID: 2135404
    [Abstract] [Full Text] [Related]

  • 14. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N, Ozaki A, Ishihara J, Sakurai M, Sasaki Y, Takahashi H, Sano T, Hoshi A.
    Gan To Kagaku Ryoho; 1986 Apr 01; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [Abstract] [Full Text] [Related]

  • 15. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
    Manda T, Shimomura K, Mukumoto S, Kobayashi K, Mizota T, Hirai O, Matsumoto S, Oku T, Nishigaki F, Mori J.
    Cancer Res; 1987 Jul 15; 47(14):3707-11. PubMed ID: 3594435
    [Abstract] [Full Text] [Related]

  • 16. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H.
    J Immunol; 1999 Jul 15; 163(2):583-9. PubMed ID: 10395644
    [Abstract] [Full Text] [Related]

  • 17. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
    Mizushima Y, Morikage T, Hirata H, Sato M, Sakamoto K, Yano S.
    J Biol Response Mod; 1988 Aug 15; 7(4):371-83. PubMed ID: 3139841
    [Abstract] [Full Text] [Related]

  • 18. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.
    Hinuma S, Naruo K, Ootsu K, Houkan T, Shiho O, Tsukamoto K.
    Immunology; 1987 Feb 15; 60(2):173-9. PubMed ID: 3493209
    [Abstract] [Full Text] [Related]

  • 19. Differing contribution of various effector cells in the elimination of syngeneic or allogeneic cells.
    Matsumoto T, Himeno K, Mitani M, Mori K, Miake S, Nomoto K.
    J Clin Lab Immunol; 1986 Feb 15; 19(2):83-9. PubMed ID: 3083105
    [Abstract] [Full Text] [Related]

  • 20. [The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].
    Wang C, Chai L, Zhu G.
    Zhonghua Zhong Liu Za Zhi; 1995 Jan 15; 17(1):27-9. PubMed ID: 7656782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.